Review outlines immune-epidermal dual-targeting strategies for psoriasis management, suggesting integrated approaches may overcome relapse and treatment resistance.
Key Points
To establish a dual-targeting therapeutic framework that disrupts pro-inflammatory feedback loops between immune cells and epidermal keratinocytes in psoriasis.
Reviewed mechanisms of inflammatory amplification driven by the interaction of immune pathways and epidermal keratinocytes.
Evaluated translational implementation approaches alongside emerging technologies, including artificial intelligence, multi-omics, engineered skin models, and targeted delivery.
Proposed three therapeutic routes: combination therapies, single agents with dual targets, and blockade of molecular bridging nodes in feedback circuits.
Demonstrated how engineered skin tissue, computational omics, and localized precision delivery can accelerate target validation and stage-specific psoriasis management.